PF-Atlas › Clinical Trials › NCT02172534

Safety, Tolerability and Pharmacokinetics of Tiotropium in Cystic Fibrosis Patients

Tiotropium bromide low · Phase 1

Registry ID
NCT02172534
Phase
Phase 1
Status
Completed
Drug / intervention
Tiotropium bromide low
Sponsor
Boehringer Ingelheim
Start
2006-09
Enrollment
113

About this trial

Study to obtain information about the safety and tolerability of tiotropium bromide administered via the Respimat® inhalation device in pediatric (≤11 y.o.) and adolescent/adult (≥12 y.o.) cystic fibrosis (CF) patients after single and multiple doses as well as to obtain pharmacokinetic data for tiotropium in CF patients after single and multiple doses

View NCT02172534 on ClinicalTrials.gov →

Explore related

All Tiotropium bromide low trialsAll IPF trials
Medical disclaimer. This page summarizes public trial data for NCT02172534 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.